Yue (Martin) Hu
About Yue (Martin) Hu
Yue (Martin) Hu is a Senior Scientist at Bristol Myers Squibb, specializing in formulation optimization, drug product development, and analytical strategy.
Company
Yue (Martin) Hu is currently employed as a Senior Scientist at Bristol Myers Squibb in the United States. He began this role on May 1, 2021. Bristol Myers Squibb is a global biopharmaceutical company known for its innovations in drug development and its focus on improving patient outcomes. Martin's role entails involvement in formulation optimization, drug product development, and analytical strategy.
Title
Yue (Martin) Hu holds the title of Senior Scientist at Bristol Myers Squibb. In this role, he leverages his extensive expertise in drug development to contribute to various pharmaceutical projects.
Education and Expertise
Martin holds a Doctor of Philosophy (Ph.D.) in Pharmaceutics and Drug Design from The University of Kansas, completed over a five-year period from 2014 to 2019. Prior to this, he earned a Master's degree in Pharmaceutical Sciences from Northeastern University between 2012 and 2014, following a Bachelor's degree in Pharmacy from Shandong University from 2007 to 2011. His expertise lies in formulation optimization, drug product development, and analytical strategy.
Background
Martin began his professional journey at Chrono Therapeutics Inc. (CTI) as a Research Scientist from 2013 to 2014 in the Greater Boston Area. He then served as a Research Scientist Intern at Boehringer Ingelheim in Ridgefield, CT for three months in 2017. Afterward, Martin joined Bristol Myers Squibb in New Brunswick, NJ, initially as a Scientist for two years from 2019 to 2021, before being promoted to his current role as Senior Scientist.
Achievements
Martin has accumulated significant experience in both academic and industry settings. His career includes internships and full-time roles that have honed his skills in pharmaceutical research and development. Notably, he contributed to research projects during his internship at Boehringer Ingelheim and has since advanced to a senior position at Bristol Myers Squibb.